213 related articles for article (PubMed ID: 34575554)
1. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
2. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
3. Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF
Mauclet C; Collard P; Ghaye B; Hoton D; Nana FA
Lung Cancer; 2021 Sep; 159():42-44. PubMed ID: 34304052
[TBL] [Abstract][Full Text] [Related]
4. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Roper N; Brown AL; Wei JS; Pack S; Trindade C; Kim C; Restifo O; Gao S; Sindiri S; Mehrabadi F; El Meskini R; Ohler ZW; Maity TK; Venugopalan A; Cultraro CM; Akoth E; Padiernos E; Chen H; Kesarwala A; Smart DK; Nilubol N; Rajan A; Piotrowska Z; Xi L; Raffeld M; Panchenko AR; Sahinalp C; Hewitt S; Hoang CD; Khan J; Guha U
Cell Rep Med; 2020 Apr; 1(1):. PubMed ID: 32483558
[TBL] [Abstract][Full Text] [Related]
5. Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring
Ding H; Zhuang Z; Xie J; Huang H; Tao Z; Liu Z
Onco Targets Ther; 2020; 13():7933-7939. PubMed ID: 32848419
[TBL] [Abstract][Full Text] [Related]
6. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF
Zeng R; Luo L; Sun X; Bao Z; Du W; Dai R; Tang W; Gao B; Xiang Y
Cancer Drug Resist; 2021; 4(4):1019-1027. PubMed ID: 35582379
[TBL] [Abstract][Full Text] [Related]
7. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Lim SM; Yang SD; Lim S; Heo SG; Daniel S; Markovets A; Minoo R; Pyo KH; Yun MR; Hong MH; Kim HR; Cho BC
Ther Adv Med Oncol; 2022; 14():17588359221079125. PubMed ID: 35251316
[TBL] [Abstract][Full Text] [Related]
8. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
[TBL] [Abstract][Full Text] [Related]
9. Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
Valet O; Swalduz A; Boussageon M; Buisson A; Avrillon V; Mastroïanni B; Pérol M
JTO Clin Res Rep; 2021 Jun; 2(6):100192. PubMed ID: 34590033
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic
Denis MG; Bennouna J
Cancer Manag Res; 2020; 12():12593-12602. PubMed ID: 33324104
[TBL] [Abstract][Full Text] [Related]
11. Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.
Kian W; Krayim B; Alsana H; Giles B; Purim O; Alguayn W; Alguayn F; Peled N; Roisman LC
Front Oncol; 2023; 13():1124949. PubMed ID: 36923435
[TBL] [Abstract][Full Text] [Related]
12. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Ribeiro MFSA; Knebel FH; Bettoni F; Saddi R; Sacardo KP; Canedo FSNA; Alessi JVM; Shimada AK; Marin JFG; Camargo AA; Katz A
NPJ Precis Oncol; 2021 Feb; 5(1):5. PubMed ID: 33580193
[TBL] [Abstract][Full Text] [Related]
13. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
14. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
Yu D; Zhao W; Vallega KA; Sun SY
Lung Cancer (Auckl); 2021; 12():1-10. PubMed ID: 33574724
[TBL] [Abstract][Full Text] [Related]
15. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
[TBL] [Abstract][Full Text] [Related]
16. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
17. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.
Chou YT; Lin CC; Lee CT; Pavlick DC; Su PL
Front Oncol; 2022; 12():838798. PubMed ID: 35372088
[No Abstract] [Full Text] [Related]
18. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.
Sun R; Hou Z; Zhang Y; Jiang B
Oncol Lett; 2022 Nov; 24(5):408. PubMed ID: 36245822
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.
Wang JL; Wang LS; Zhu JQ; Ren J; Wang D; Luo M
Respirol Case Rep; 2022 Nov; 10(11):e01054. PubMed ID: 36258694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
